Nebyol (Nebivolol)

Nebivolol, the active ingredient in Nebyol, is a beta‑adrenergic receptor blocker presented as an oral dosage form for oral use. It treats hypertension and heart failure by lowering blood pressure and improving cardiac function in adult patients.

GNH USA supplies Nebyol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol acts on the cardiovascular system to control blood pressure and support heart function.

Hypertension: lowers systolic and diastolic pressure to reduce cardiovascular risk. Heart failure (reduced ejection fraction): improves ventricular performance and symptoms. Left ventricular dysfunction: enhances cardiac output and exercise tolerance.

Nebivolol may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness: especially after standing. - Fatigue or tiredness: often improves with continued use. - Bradycardia: slower than normal heart rate. - Peripheral edema: swelling of ankles or feet. - Nasal congestion: mild blockage of nasal passages.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Heart block: impaired electrical conduction in the heart. - Hypotension: dangerously low blood pressure. - Bronchospasm: airway narrowing in patients with asthma or COPD. - Allergic reactions: rash, itching, or angio‑edema. - Hepatic dysfunction: abnormal liver enzymes or jaundice.

Before initiating nebivolol therapy, clinicians should evaluate patient-specific factors and monitor for potential complications.

Monitor blood pressure: ensure adequate control without excessive drop. Assess cardiac function: review baseline heart rate and ECG. Review concomitant beta‑blockers: avoid additive effects. Caution in asthma/COPD: risk of bronchospasm. Adjust in renal impairment: dose may need modification. Store at room temperature: keep in original pack, protect from moisture.

Nebivolol can interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Other beta‑blockers: may cause excessive bradycardia. - Calcium channel blockers (verapamil, diltiazem): increase risk of AV block. - CYP2D6 inhibitors (paroxetine, fluoxetine): raise nebivolol plasma levels. - Antihypertensives (ACE inhibitors, diuretics): additive hypotensive effect. - Anticholinergic agents: may worsen bronchospasm.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and blood pressure. - NSAIDs: may blunt antihypertensive response. - Antidiabetic drugs: mask hypoglycemia symptoms. - Antidepressants (serotonergic): observe for heart rate changes. - Lipid‑lowering agents: no major effect but monitor overall therapy.